SereNeuro Therapeutics
- Biotech or pharma, therapeutic R&D
SereNeuro Therapeutics is developing non-opioid, first-in-class, DMOAD SN101 iPS cell therapy for chronic knee osteoarthritis pain and sequelae.
June 16-19, 2025
Boston Convention & Exhibition Center
SereNeuro Therapeutics is developing non-opioid, first-in-class, DMOAD SN101 iPS cell therapy for chronic knee osteoarthritis pain and sequelae.